The immunoreactivity of Bcl-2 was significantly decreased after progestin medication, and tumor cell maturation was also observed in the progestin-responsive group, indicating that Bcl-2 downregulation may be closely related to squamous differentiation of EC [27]. Here, BCL2 is linked to neoplasm.